Scott H. Donaldson

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation

Frank J. Accurso, Steven M. Rowe, John P. Clancy et al. · New England Journal of Medicine · 2010 · 802 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Mucus Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline

Scott H. Donaldson, William D. Bennett, Kirby L. Zeman et al. · New England Journal of Medicine · 2006 · 689 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis

Steven M. Rowe, Sonya L. Heltshe, Tanja Gonska et al. · American Journal of Respiratory and Critical Care Medicine · 2014 · 498 citations

Medicine, Pharmacology, Pharmacotherapy +17

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

John P. Clancy, Steven M. Rowe, Frank J. Accurso et al. · Thorax · 2011 · 496 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16